Hesham is a seasoned physician-scientist who uniquely combines his personal experience with deep clinical expertise to identify transformational opportunities for advancing cancer care and treatment.

With over 20 years in global research, Hesham has successfully led the development and registration of 12 precision oncology products and set numerous drug development precedents across multiple global pharmaceutical companies. His expertise encompasses both early and late stages of development across solid tumors, and hematological malignancies.

Under his leadership, GSK’s Oncology Therapeutic Area has established a portfolio of cornerstone assets, transforming promising molecules into effective medicines. Hesham oversees more than 300 researchers around the world and leads the development of GSK’s Oncology pipeline of more than 15 clinical-stage assets targeting patient populations with high unmet needs. Hesham utilizes innovative translational approaches and advanced technologies like artificial intelligence, digital pathology, and tumor modeling, to advance the
development of GSK’s next generation of cancer therapies.

Hesham applies patient data driven approaches that lead to the development of medicines that make a meaningful difference in patients’ lives. With roots deeply tied to the Middle East, Hesham has led efforts to promote clinical studies in the region, and he has spearheaded initiatives to promote research and clinical trials within the Middle East, driving collaborative efforts with local oncology teams to research precision medicine and data driven approaches to cancer treatments.

Hesham holds an MD from the University of Cairo School of Medicine and a Master’s degree in Regulatory Sciences from the University of Southern California (USC). He is currently pursuing a Doctoral degree in Regulatory Sciences at USC.